ClinicalTrials.gg
Not yet recruitingNCT05660213Updated May 20, 2025

A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer

An observational study in Unresectable Hepatocellular Carcinoma, sponsored by Fudan University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-20.

Sponsored by Fudan University · Observational

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
750
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Carcinoma, Hepatocellular by Fudan University — 17 open to participants now, 18 under way, none of them phase 3. Carcinoma, Hepatocellular · Fudan University.

Started
2025
with 8 others
Observational
4 of 48
3 open now
Primary completion
2027-08
later than 13 of 17 live
Registered
33rd of 48
by date

Among the 48 studies in Carcinoma, Hepatocellular by Fudan University, this one is one of 9 that started in 2025, is one of 4 observational ones, reaches primary completion later than 13 of the 17 other live ones, and was the 33rd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

17 of the 48 studies in Carcinoma, Hepatocellular by Fudan University are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Carcinoma, Hepatocellular by Fudan University, or all of them as a file.
02

Study summary

This study is a multicenter, registered research aimed at evaluating the efficacy of different treatment regimens in the treatment of unresectable CNLC liver cancer stage III hepatocellular carcinoma

Read the detailed description

This study is a multicenter, observational, natural cohort registration study. We plan to continuously include 750 subjects diagnosed with unresectable CNLC stage III hepatocellular carcinoma (HCC) at selected research centers. According to the actual clinical diagnosis and treatment plan of patients, the following treatment modes will be included in the Cohort of patients:

Cohort A: Targeted drugs combined with anti-PD-1/PD-L1 antibodies Cohort B: TACE (transarterial chemoembolization) combined with targeted/immunotherapy Cohort C: Lenvatinib monotherapy Cohort D: Huaier granules combined with any of the above Cohorts for treatment Throughout the entire study period, it is planned to recruit patients who have visited the selected research center within 12 months (December 2024 to December 2025). Each individual subject will be followed up every 8 weeks until the diagnosis and treatment mode changes, disease progression progresses, or the patient withdraws from the study or dies for any reason, whichever occurs first.

03

Conditions studied

  • Unresectable Hepatocellular Carcinoma

Keywords

  • Huaier granules
  • Unresectable hepatocellular carcinoma
  • curative effect
  • safety
  • Anti-PD-1/PD-L1 antibody drugs
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

During the whole study period, a total of 750 patients in the selected research centers from December 2024 to December 2025 were planned to be recruited consecutively, including 150 in cohort a, 150 in cohort B, 150 in cohort C, and 300 in cohort D. A single subject was visited every 8 weeks after enrollment until the diagnosis and treatment mode changed, disease progression or the patient withdrew from the study or died for any reason, whichever occurred first. The maximum duration of a single subject's total visit shall not exceed 24 months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

·≥ 18 years old;

  • Diagnosed as unresectable hepatocellular carcinoma through histopathological and/or cytological examination, or meeting the clinical diagnostic criteria for hepatocellular carcinoma in the 2022 edition of the guidelines for the diagnosis and treatment of primary liver cancer;
  • CNLC liver cancer stage III;
  • Liver function A or B grade 7 points;
  • Has not received systematic treatment in the past;
  • Patients with active infection who meet one of the following conditions can be enrolled: ① Within 28 days before enrollment, the patient's HBV DNA is less than 500 IU/mL. If they have received anti HBV treatment, they need to continue their original antiviral treatment; If anti HBV treatment has not been received, it is necessary to receive anti HBV treatment throughout the entire course of medication (according to local treatment standards; for example, entecavir); ② For patients with HBV DNA>500 IU/mL and who have not received antiviral therapy, they must receive at least 7 days of antiviral therapy (according to local treatment standards; for example, entecavir) before enrollment in this study, and are willing to continue receiving antiviral therapy during the study. Before enrollment, the serum HBV-DNA virus should be retested to decrease by more than 1 log value For patients with HBV DNA>500 IU/mL and who have received antiviral therapy, they must receive at least 7 days of antiviral therapy (according to local treatment standards; for example, entecavir) before enrollment in this study, and are willing to continue receiving antiviral therapy during the study. Serum HBV-DNA virus levels should be retested before enrollment;
  • Active infected individuals with stable disease status after treatment;
  • At least one tumor lesion available for evaluation;
  • Clear consciousness, language expression ability or reading ability, able to communicate normally, and cooperate to complete the questionnaire evaluation;
  • Voluntarily join this study and sign an form.

Exclusion criteria

Exclusion Criteria:

  • Simultaneously having two or more active primary malignant tumors;
  • Portal vein cancer thrombus invades the superior mesenteric vein;
  • Received radiation therapy within the past 4 weeks;
  • Expected survival time is less than 3 months;
  • Pregnant or lactating women or those planning to conceive;
  • Coagulation dysfunction (>2.0, PT>16 s) or diseases with a strong likelihood of bleeding (including but not limited to esophageal and/or gastric variceal bleeding, active ulcers, uncontrolled hypertension);
  • Refusing to cooperate with follow-up visits;
  • Other reasons led the researchers to believe that it was not suitable to participate in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
750 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort A

    Targeted drugs combined with anti-PD-1 / PD-L1 antibodies

    Drug: Targeted drugs combined with anti-PD-1/PD-L1 antibodies

  • Cohort B

    TACE (transarterial chemoembolization) combined with target immunotherapy

    Drug: TACE (transarterial chemoembolization) combined with targeted/immunotherapy

  • Cohort C

    Lenvatinib monotherapy

    Drug: Lenvatinib monotherapy

  • Cohort D

    Huaier granules combined with any of the above Cohorts for treatment

    Drug: Huaier granules combined with any of the above Cohorts for treatment

Interventions

  • DrugTargeted drugs combined with anti-PD-1/PD-L1 antibodies

    Targeted drugs combined with anti-PD-1/PD-L1 antibodies

  • DrugTACE (transarterial chemoembolization) combined with targeted/immunotherapy

    TACE (transarterial chemoembolization) combined with targeted/immunotherapy

  • DrugLenvatinib monotherapy

    For patients weighing less than 60 kg, the recommended daily dose of this product is 8 mg (2 capsules of 4 mg), once daily; For patients weighing ≥ 60 kg, the recommended daily dose of this product is 12 mg (3 capsules of 4 mg), once daily. Treatment should be continued until disease progression or intolerable toxic reactions occur.

  • DrugHuaier granules combined with any of the above Cohorts for treatment

    Drug page: Huaier Extract GranuleStudies of Huaier Extract GranuleHuaier Extract Granule pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral administration of Huaier granules, 10g each time, 3 times a day, until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that there is no longer any benefit.It is recommended that the date of first use of Huaier granules be determined by the researchers, and after disease progression, the researchers and patients should jointly decide whether to continue receiving Huaier granules treatment.

    Also known as: Z20000109#NMPA Approval Number#

This study also gives LenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. ORRObjective response rate (ORR)

    It defined as the proportion of subjects who achieve complete response (CR) or partial response (PR) in primary tumor imaging evaluation.

    Time frame: start of treatment until 24-month follow-up

  2. Progression free survival (PFS)

    It defined as the time from the date the subject first receives combination therapy until the first observation of tumor progression or death from any cause.

    Time frame: Start of treatment until 24-month follow-up

  3. Disease control rate (DCR)

    It defined as the proportion of subjects who achieve complete response (CR), partial response (PR), or disease stability (SD) as assessed by primary tumor imaging.

    Time frame: Start of treatment until 24-month follow-up

  4. Time to Response(TTR)

    It defined as the time from the date the subject first receives combination therapy to the first observation of tumor response (CR or PR).

    Time frame: Start of treatment until 24-month follow-up

  5. Duration of Response (DoR)

    It defined as the time from the first observation of tumor remission (CR or PR) in a subject receiving combination therapy to the first observation of tumor progression or death from any cause.

    Time frame: Start of treatment until 24-month follow-up

  6. Overall survival (OS):

    It defined as the time from the day of randomization of patients to death from any cause.

    Time frame: Start of treatment until 24-month follow-up

Secondary outcomes

  1. Quality of Life Score

    Evaluation using the EORTC QLQ-C30 (Chinese version) core quality of life scale developed by the European Organization for Cancer Research and Treatment.

    Time frame: Start of treatment until 24-month follow-up

  2. The incidence and severity of adverse events (AE) and severe adverse events (SAE)

    The definition and severity grading of AE and SAE refer to the corresponding descriptions in the definition and evaluation section of adverse events, and the incidence rate is defined as the proportion of patients with AE and SAE to the corresponding total population.

    Time frame: Start of treatment until 24-month follow-up

  3. The incidence and severity of adverse reactions (ADR), severe adverse reactions (SADR), suspicious and unexpected severe adverse reactions (SUSAR)

    The definition and severity grading of ADR, severe ADR, and SUSAR refer to the corresponding descriptions in the definition and evaluation section of adverse events. The incidence rate is defined as the proportion of patients with ADR, severe ADR, and SUSAR to the corresponding total population.

    Time frame: Start of treatment until 24-month follow-up

  4. The incidence and severity of Adverse Events of Special Concern (AESI)

    AESI includes proteinuria, enteritis, and immune-mediated myocarditis. The incidence is defined as the proportion of patients who experience AESI to the corresponding total population, and the severity grading refers to the corresponding description in the definition and evaluation section of adverse events.

    Time frame: Start of treatment until 24-month follow-up

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Aug 2027, 24 months later.

Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 24 months is below that.

Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2022
First posted
Dec 21, 2022
StartEst.
Aug 2025
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2030
Last update
May 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05660213
Lead sponsor
Fudan University
Collaborators
LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
Responsible party
Jia Fan (Professor, Fudan University) — Principal investigator
First posted
Dec 21, 2022
Start date
Aug 2025 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Aug 2030 (estimated)
Last update
May 20, 2025

Study contacts

Jia Fan, PhD
Contact
Fan.jia@zs-hospital.sh.cn
+86 021-64041990
Huichuan Sun, PhD
Contact
Sun.huichuan@zs-hospital.sh.cn
+86 021-64041990
Jia Fan, PhD
principal investigator · Affiliated Zhongshan Hospital, Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion